Hans Hull is Chief Business Officer at PLIANT THERAPEUTICS, INC. (PLRX). They have made 1 open-market trade across 1 company since 2015, most recently 2025-01-23.
CIK 0001614876
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PLRX | SELL · 10b5-1 | 2025-01-17 | 2025-01-22 | $11.20 | $357K | +4.1% | -71.3% | -86.0% |
| PLRX | SELL · 10b5-1 | 2024-07-10 | 2024-07-12 | $11.56 | $114K | -2.5% | -8.9% | -10.8% |
| PLRX | SELL · 10b5-1 | 2024-01-17 | 2024-01-19 | $17.23 | $337K | +7.4% | -6.8% | -26.9% |
| PLRX | SELL · 10b5-1 | 2023-08-03 | 2023-08-07 | $20.01 | $1.1M | -8.2% | -8.6% | -17.0% |
| PLRX | SELL · 10b5-1 | 2023-07-17 | 2023-07-19 | $18.01 | $646K | +0.2% | -5.8% | -17.0% |
| PLRX | SELL · 10b5-1 | 2023-03-30 | 2023-04-03 | $26.52 | $479K | +0.2% | -9.7% | -31.9% |
| PLRX | SELL | 2022-12-20 | 2022-12-21 | $19.10 | $334K | -1.3% | +18.3% | +44.6% |
| [AAVL] | SELL · 10b5-1 | 2015-06-04 | 2015-06-05 | $37.64 | $75K | N/A | N/A | N/A |
| AAVL | SELL · 10b5-1 | 2015-05-04 | 2015-05-06 | $30.87 | $154K | N/A | N/A | N/A |
| AAVL | SELL · 10b5-1 | 2015-04-07 | 2015-04-08 | $38.61 | $1.1M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.